2 ASX healthcare shares to buy that you've not heard of: expert

If you want to invest in a sector that people still need during economic downturns, here's a pair of small caps that might interest you.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healthcare is one of those industries that enjoys relatively stable demand through tougher economic times.

With consecutive interest rises forcing Australians to close their wallets, this might be a consideration for the coming period.

But of course, the well-known ASX shares in the sector are already well bought.

So one Wilson Asset Management analyst has dug deeper into his research to come up with a couple of buys that are not yet household names:

'This company can re-rate over the next few years'

Probiotec Limited (ASX: PBP) only has a market capitalisation of $180 million. 

But for such a small cap it has managed to hold its stock price pretty well in 2022, only down 1.76% so far.

Wilson senior equity analyst Sam Koch is buying the pharmaceutical manufacturer and distributor.

"We believe the stock offers investors valuation and earnings upside," he said in a Wilson video.

"What the market's missing here is their ability to compound earnings growth at a very high rate, relative to its current valuation."

The business' "strong organic growth" is accompanied by bolt-on acquisitions, he added.

"Trading at 10 times P/E with over 15% [earnings per share] growth projected, we believe that this company can re-rate over the next few years."

While coverage is sparse on Probiotec, at least Shaw and Partners currently agrees with Koch, rating the stock as a strong buy.

Probiotec hands out a 2.5% dividend yield.

Share price now below PE ratio of ONE

CogState Limited (ASX: CGS) is arguably a technology business in addition to its involvement in the health sector.

That's because it's a cognitive science company that provides tech and services to biotechnology and pharmaceutical clients conducting clinical trials.

Koch said that big pharma relies on CogState's technology for their studies into Alzheimer's Disease.

"What we're really attracted to in CogState is that they were one of the first companies to provide the software-first technology, which has accelerated the industry's push towards decentralised clinical trials."

The value of CogState's services was recognised in one of its largest clients actually taking a 7% shareholding, according to Koch.

"The company's trading at below one times earnings-to-price growth multiple with over 15% of the market cap caught up in cash," he said.

"We believe that acquisitions and earnings upgrades will drive the stock from here."

According to CMC Markets, three of four analysts currently rate the stock as a strong buy.

The CogState share price has dropped more than 19% so far this year.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CogState Limited and Probiotec Limited. The Motley Fool Australia has positions in and has recommended CogState Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »